(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Vote in favor of Your Number one Cake Type - 2Trump says Venezuela will start 'turning over' oil to the U.S. Is that the reason he toppled Maduro — or is it something else?
- 3What’s the shadowy organisation taking Gaza Palestinians to South Africa?
- 4New York to require social media platforms to display mental health warnings
- 5The gay hockey show no one saw coming — and everyone is suddenly obsessed with
- Ghassan Al-Duhaini to replace Abu Shabab as Popular Forces leader in Gaza
- A top Marine shares his secrets to keeping fit at 50
- Steinmeier honours Italian 'guest workers' who rebuilt German economy
- Best Amusement Park in Asia: Which One Is a Must-Visit
- Doctors say changes to US vaccine recommendations are confusing parents and could harm kids
- A decade after Brazil’s deadly dam collapse, Indigenous peoples demand justice on the eve of COP30
- Virtual reality opens doors for older people to build closer connections in real life
- Moving Pool Highlights for 2024
- The most effective method to Augment Benefits in Gold Speculation: Systems and Tips
